06.06.12
Laura Jones, Ph.D., has been appointed vice president of quality and regulatory affairs at Avrio Biopharmaceuticals. Dr. Jones will be responsible for leading and overseeing Avrio’s quality and regulatory compliance systems.
“With more than 25 years of experience in the pharmaceutical and biopharmaceutical industries, Laura offers a wealth of knowledge and experience in quality assurance and regulatory affairs,” said William Botha, president of Avrio Biopharma. “I am confident knowing that Laura’s in-depth expertise will even further enhance Avrio’s robust quality systems to continuously improve the quality of service Avrio provides its clients.”
Dr. Jones has served quality assurance and regulatory affairs management roles supporting the pharmaceutical, biopharmaceutical, and medical device industries. Dr. Jones joins the company from Bayer HealthCare, where she served as quality assurance director. Prior to Bayer, she held leadership roles at Valeant Pharmaceuticals International, Inc. (PII), Medtronic, Elan Pharmaceuticals, and Amphastar Pharmaceuticals.
“With more than 25 years of experience in the pharmaceutical and biopharmaceutical industries, Laura offers a wealth of knowledge and experience in quality assurance and regulatory affairs,” said William Botha, president of Avrio Biopharma. “I am confident knowing that Laura’s in-depth expertise will even further enhance Avrio’s robust quality systems to continuously improve the quality of service Avrio provides its clients.”
Dr. Jones has served quality assurance and regulatory affairs management roles supporting the pharmaceutical, biopharmaceutical, and medical device industries. Dr. Jones joins the company from Bayer HealthCare, where she served as quality assurance director. Prior to Bayer, she held leadership roles at Valeant Pharmaceuticals International, Inc. (PII), Medtronic, Elan Pharmaceuticals, and Amphastar Pharmaceuticals.
